

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | |
|---|---|--|---|
| 1. Name and Address of Reporting Person* <u>Garella Rahul</u> (Last) (First) (Middle) C/O ENDO INTERNATIONAL PLC FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD (Street) BALLSBRIDGE, L2 DUBLIN (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2019 | 3. Issuer Name and Ticker or Trading Symbol <u>Endo International plc [ENDP]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP, Intl Pharmaceuticals | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|---|
| Ordinary Shares | 24,116 | D | |
| 2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽¹⁾ | 236 | D | |
| 2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽²⁾ | 353 | D | |
| 2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽³⁾ | 3,538 | D | |
| 2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁴⁾ | 16,047 | D | |
| 2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁵⁾ | 39,700 | D | |
| 2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁶⁾ | 26,902 | D | |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|--|--|---|
| | Date Exercisable | Expiration Date | | | | |
| 2015 Stock Incentive Plan Options (NQ) ⁽⁷⁾ | (7) | 10/01/2025 | Ordinary Shares 3,422 | 70.02 | D | |
| 2015 Stock Incentive Plan Options (NQ) ⁽⁸⁾ | (8) | 02/23/2026 | Ordinary Shares 4,764 | 50.22 | D | |
| 2015 Stock Incentive Plan Options (NQ) ⁽⁹⁾ | (9) | 02/21/2027 | Ordinary Shares 23,810 | 13.19 | D | |
| 2015 Stock Incentive Plan Options (NQ) ⁽¹⁰⁾ | (10) | 08/10/2027 | Ordinary Shares 54,707 | 7.55 | D | |

Explanation of Responses:

- On October 1, 2015, 946 RSUs were granted to Mr. Garella with one-fourth vesting, and thus expiring, on each of the first four grant date anniversaries. As of August 1, 2019, 710 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
- On February 23, 2016, 1,412 RSUs were granted to Mr. Garella with one-fourth vesting, and thus expiring, on each of the first four grant date anniversaries. As of August 1, 2019, 1,059 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
- On February 21, 2017, 10,614 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries. As of August 1, 2019, 7,076 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
- On August 10, 2017, 24,071 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries. As of August 1, 2019, 8,024 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
- On April 2, 2018, 59,551 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries. As of August 1, 2019, 19,851 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
- On March 29, 2019, 26,902 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries.

7. On October 1, 2015, 3,422 non-qualified stock options were granted to Mr. Garella with one-fourth vesting on each of the first four grant date anniversaries. As of August 1, 2019, 2,567 non-qualified stock options were vested and released.

8. On February 23, 2016, 4,764 non-qualified stock options were granted to Mr. Garella with one-fourth vesting on each of the first four grant date anniversaries. As of August 1, 2019, 3,573 non-qualified stock options were vested and released.

9. On February 21, 2017, 23,810 non-qualified stock options were granted to Mr. Garella with one-fourth vesting on each of the first four grant date anniversaries. As of August 1, 2019, 11,906 non-qualified stock options were vested and released.

10. On August 10, 2017, 54,707 non-qualified stock options were granted to Mr. Garella with one-third vesting on each of the first three grant date anniversaries. As of August 1, 2019, 18,236 non-qualified stock options were vested and released.

Remarks:

On July 30, 2019, Endo International plc appointed Mr. Garella as EVP, International Pharmaceuticals. These securities represent the amounts owned by Mr. Garella as of August 1, 2019, the date of effectiveness of his appointment.

/s/ Yoon Ah Oh, by power of 08/09/2019
attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Matthew J. Maletta, Yoon Ah Oh, Carrie A. Nichol, Justin Dailey and Sarah Beck as the undersigned's true and lawful attorneys-in-fact,
(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Endo International plc, an Irish public limited company (the "Company"), with the U
(2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators
(3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;
 - (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-
 - (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to
 - (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16.
- The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing

This Power of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1 day of August 2019.

SIGNATURE

TITLE

/S/ RAHUL GARELLA Executive Vice President, International Pharmaceuticals
NAME: Rahul Garella

STATE OF Dublin, Ireland:
COUNTY OF Dublin, Ireland:

On this 1 day of August 2019, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instrument for the purposes therein contained.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/S/ JAMES JONES
Notary Public